Form 4 for RLMD RELMADA THERAPEUTICS, INC.
Accepted 2022-04-05 00:00:00 ET · period of report 2022-04-04 · accession 0001213900-22-018223 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-05 | 2022-04-04 | RLMD | Kelly Paul Edward | Dir | S - Sale+OE | $30.04 | -10.0K | 187.3K | -5% | -$300.4K |
| D | 2022-04-05 | 2022-04-04 | RLMD | Kelly Paul Edward | Dir | M - OptEx | $3.24 | +10.0K | 197.3K | +5% | +$32.4K |
| D | 2022-04-05 | 2022-04-04 | RLMD | Kelly Paul Edward | Dir | M - OptEx | $0.00 | -10.0K | 20.5K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-04 | S | D | 10,000 | $30.04 | 187,295 | D | — | — | (F2) The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. (F3) Sales prices range from $30.00 to $30.20 per share, inclusive. |
| 2 | Common | Common Stock | 2022-04-04 | M | A | 10,000 | $3.24 | 197,295 | D | — | — | |
| 3 | Derivative | Options to purchase common stock | 2022-04-04 | M | D | 10,000 | $0.00 | 20,500 | D | $3.24 · 2017-10-20 to 2027-10-20 | 10,000 Common Stock | (F4) The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. |